As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
Eagerly pursuing all the latest fads and trends.